Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow VCRE by emailGet an email when VCRE reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about VCRE, unsubscribe in one click. Privacy
📣 What VCRE Says Is Next
mid-2027 · “Shortly after the period ended, the independent Data Monitoring Committee recommended that ASPIRE continue as planned following a pre-planned futility analysis, keeping us on track for topline results expected in mid-2027, ” said Ahmed Mousa, Chief Executive Officer of Vicore Pharma.”
Company press release, Nov 5, 2026 · SEC filing
mid-2027 · “With 378 patients enrolled and a 52-week FVC primary endpoint, ASPIRE was built to generate a high-quality dataset, and our focus remains on disciplined execution through database lock and expected topline results in mid-2027,” said Ahmed Mousa, Chief Executive Officer of Vicore Pharma.”
Company press release, Oct 22, 2026 · SEC filing
mid-2027 · “ASPIRE continues as planned and remains on track to report 52-week topline results in mid-2027.”
Company press release, Oct 22, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 5, 2026 ·
Earnings Vicore Pharma announced unaudited third quarter 2026 financial results for the period ended September 30, 2026, detailed in an interim report and press release attached as exhibits. Form 6-K · SEC filing · Press release
Nov 3, 2026 ·
Leadership Vicore announced the members of its Nomination Committee for the May 5, 2027 AGM: Staffan Lindstrand (HealthCap VII), Jan Särlvik (Fourth Swedish National Pension Fund), Ivo Staijen (HBM Healthcare) and chairman Hans Schikan. Shareholder proposals are due by January 15, 2027. Form 6-K · SEC filing · Press release
Oct 22, 2026 ·
Clinical trial Passed a pre-planned futility analysis for the Phase 2b ASPIRE trial of buloxibutid in IPF; the Data Monitoring Committee recommended the trial continue without modification and noted no safety concerns. Form 6-K · SEC filing · Press release
Sep 30, 2026 ·
Vicore reported that its outstanding shares and votes rose by 118,916 after warrant exercises and share deliveries to participants in its Board LTIP 2023, Board LTIP 2024 and Board RSU 2025 programs. Total registered shares and votes now stand at 281,644,509. Form 6-K · SEC filing · Press release
Aug 21, 2026 ·
Earnings Reported Q2 2026 net revenues of SEK 2.2 million and operating loss of SEK 150.1 million, with cash, equivalents and short-term investments of SEK 905.6 million (USD 93.0 million) at June 30, 2026. Completed enrollment in the Phase 2b ASPIRE trial, with topline data expected mid-2027. Form 6-K · SEC filing · Press release
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
May 2027 · Phase 2 · Active Trial · A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not VCRE's own candidates): Caffeine, Sodium Nitroprusside.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VCRE and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.